JP2022513126A - 脱毛治療又は毛髪成長促進用の組成物 - Google Patents
脱毛治療又は毛髪成長促進用の組成物 Download PDFInfo
- Publication number
- JP2022513126A JP2022513126A JP2021529142A JP2021529142A JP2022513126A JP 2022513126 A JP2022513126 A JP 2022513126A JP 2021529142 A JP2021529142 A JP 2021529142A JP 2021529142 A JP2021529142 A JP 2021529142A JP 2022513126 A JP2022513126 A JP 2022513126A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- hair
- serum
- silk
- silk protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 84
- 230000003676 hair loss Effects 0.000 title claims abstract description 51
- 208000024963 hair loss Diseases 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 230000003779 hair growth Effects 0.000 title claims abstract description 46
- 210000002966 serum Anatomy 0.000 claims abstract description 72
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 70
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 70
- 230000001737 promoting effect Effects 0.000 claims abstract description 25
- 239000000499 gel Substances 0.000 claims description 19
- 239000002674 ointment Substances 0.000 claims description 13
- 239000002453 shampoo Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- -1 byssus Proteins 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 108010013296 Sericins Proteins 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 239000002537 cosmetic Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 244000144972 livestock Species 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 102000016942 Elastin Human genes 0.000 claims description 3
- 108010014258 Elastin Proteins 0.000 claims description 3
- 108010022355 Fibroins Proteins 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229920002549 elastin Polymers 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 235000015961 tonic Nutrition 0.000 claims description 3
- 230000001256 tonic effect Effects 0.000 claims description 3
- 229960000716 tonics Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 210000002381 plasma Anatomy 0.000 description 77
- 210000004209 hair Anatomy 0.000 description 40
- 231100000360 alopecia Toxicity 0.000 description 29
- 238000000034 method Methods 0.000 description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012888 bovine serum Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 5
- 229920001872 Spider silk Polymers 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010068168 androgenetic alopecia Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000241413 Propolis Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 201000002996 androgenic alopecia Diseases 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 239000007952 growth promoter Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 230000003658 preventing hair loss Effects 0.000 description 3
- 229940117382 propecia Drugs 0.000 description 3
- 229940069949 propolis Drugs 0.000 description 3
- 229940107889 rogaine Drugs 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- SNPLKNRPJHDVJA-UHFFFAOYSA-N dl-panthenol Chemical compound OCC(C)(C)C(O)C(=O)NCCCO SNPLKNRPJHDVJA-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000004023 fresh frozen plasma Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000031774 hair cycle Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 238000001728 nano-filtration Methods 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000003797 telogen phase Effects 0.000 description 2
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- ZIMGGGWCDYVHOY-UHFFFAOYSA-N 3-hydroxy-2-imino-6-(1-piperidinyl)-4-pyrimidinamine Chemical compound N=C1N(O)C(N)=CC(N2CCCCC2)=N1 ZIMGGGWCDYVHOY-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001605 Dextranomer Polymers 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 235000008247 Echinochloa frumentacea Nutrition 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000004072 Panicum sumatrense Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000005250 alkyl acrylate group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 208000034557 congenital alopecia Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 229940124563 hair growth stimulant Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003774 positive effect on hair Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940046651 testosterone 40 mg Drugs 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/983—Blood, e.g. plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
ウシ胎児血清(FBS,Fetal Bovine Serum; Biofluids.Inc,Rockville,MD)を冷凍乾燥用の試料瓶に500ml入れ、-80℃冷凍機(Forma Scientific,Inc.Ohio,USA)で6時間冷凍させた。この時、FBSは、耐毒素容量が0.1ng/ml以下であり、ヘモグロビン容量が30ng/100ml以下であるものを使用した。冷凍したFBSが入っている試料瓶を冷凍乾燥/シェル冷凍システム(Labconco,Co.Kansas City,Missouri.USA)に装着後にシステムを作動し、-48℃で7日間冷凍乾燥させて粉末剤を製造した。このとき、全過程を無菌的な条件で行った。
実施例1で製造した粉末(5重量部)を、95重量部の成分(Carbopol ETD2020 38mg、グリセリン116mg、プロピレングリコール38mg、トリエタノールアミン192mg及び適当量の精製水)と混合してpH5.8~6.0の澄明なゲル剤を得た。Carbopol ETD 2020は、C10-30アルキルアクリレート交差重合体を有するアクリレートである。
5週齢の白鼠(400~500g,Sprague-Dawley系)8匹の背部位を完全に除毛するために、毛を剃った後、除毛剤(Mouse removal cream;Veet)を1匹当たり20~30gを塗り、5分後に除毛クリームを拭き取って毛を完全に除去した。毛の除去された部位にテストステロン40mg/ゲルを2g/匹で毎日3週間に朝と夕方に2回ずつ塗りながら、3週後に毛が生えなかった4匹を選択して除毛を再反復した。
実施例3と同じ方法で準備した実験用白鼠4匹に、それぞれ、対照群ゲル、血漿及び血清を含むゲル、セリシンタンパク質(Sigma-Aldrich)だけを含むゲル、及び血漿粉とセリシンタンパク質を含むゲルを、脱毛部位に3g/匹/日で1週間処理した。
実施例2で製造したウシ血清粉末5g、組換えクモシルクタンパク質50g、界面活性剤であるオリベム(登録商標)(Sodium PEG-7 olive oil Carboxylate)150g、アミノ酸(Acmino Acid)150g、ハバスベタイン(Babassuamidopropyl Betaine)150g添加物であるビュープレックス(Beauplex Vitamen)30g、パンテノール(DL-panthenol)45g、フィチン酸(Phytic Acid)24g、プロポリス(Propolis Extract)30g、マルチナチュロティックス(MultiEx Naturotics)60g、クエン酸(Citric Acid)6gを撹拌機に入れて約25rpmの速度で撹拌し、シャンプー1を3000g製造した。
Claims (13)
- 血漿又は血清成分とシルクタンパク質とを有効成分として含有する、毛髪成長促進又は脱毛抑制用の医薬組成物。
- 前記血漿又は血清は、ヒト又は家畜から由来したものであることを特徴とする、請求項1に記載の組成物。
- 前記シルクタンパク質は、自然由来又は組換えシルクタンパク質から由来したものであることを特徴とする、請求項1に記載の組成物。
- 前記シルクタンパク質は、ドラグラインシルク(dragline silk)、エラスチン(elastin)、シルクフィブロイン(silk fibroin)、ビサス(byssus)、セリシン(sericin)、鞭毛状シルク(flagelliform silk)及びコラーゲン(collagen)からなる群から選ばれるタンパク質を構成する反復単位ペプチドであることを特徴とする、請求項1に記載の組成物。
- 前記シルクタンパク質は、グリシン或いはセリン含有量が1%以上であるペプチドが1~160回反復されている構造を有することを特徴とする、請求項1に記載の組成物。
- 前記シルクタンパク質は、5~300kDaの分子量を有することを特徴とする、請求項1に記載の組成物。
- シャンプー、クリーム、ローション、トニック、スプレー、エアゾール、オイル、溶液、懸濁液、ゲル及び軟膏からなる群から選ばれる剤形であることを特徴とする、請求項1に記載の組成物。
- 血漿又は血清成分とシルクタンパク質とを有効成分として含有する毛髪成長促進又は脱毛抑制用の化粧料組成物。
- 前記血漿又は血清は、ヒト又は家畜から由来したものであることを特徴とする、請求項8に記載の組成物。
- 前記シルクタンパク質は、自然由来又は組換えシルクタンパク質から由来したものであることを特徴とする、請求項8に記載の組成物。
- 前記シルクタンパク質は、ドラグラインシルク(dragline silk)、エラスチン(elastin)、シルクフィブロイン(silk fibroin)、ビサス(byssus)、セリシン(sericin)、鞭毛状シルク(flagelliform silk)及びコラーゲン(collagen)からなる群から選ばれるタンパク質を構成する反復単位ペプチドであることを特徴とする、請求項8に記載の組成物。
- 前記シルクタンパク質は、グリシン或いはセリン含有量が1%以上であるペプチドが1~160回反復されている構造を有することを特徴とする、請求項8に記載の組成物。
- 前記シルクタンパク質は、5~300kDaの分子量を有することを特徴とする、請求項8に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2018-0146288 | 2018-11-23 | ||
KR1020180146288A KR102363366B1 (ko) | 2018-11-23 | 2018-11-23 | 탈모 치료 또는 모발 성장 촉진용 조성물 |
PCT/KR2019/016012 WO2020106075A1 (ko) | 2018-11-23 | 2019-11-21 | 탈모 치료 또는 모발 성장 촉진용 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022513126A true JP2022513126A (ja) | 2022-02-07 |
JP7315675B2 JP7315675B2 (ja) | 2023-07-26 |
Family
ID=70773558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021529142A Active JP7315675B2 (ja) | 2018-11-23 | 2019-11-21 | 脱毛治療又は毛髪成長促進用の組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220040261A1 (ja) |
EP (1) | EP3884951A4 (ja) |
JP (1) | JP7315675B2 (ja) |
KR (1) | KR102363366B1 (ja) |
CN (1) | CN113226339A (ja) |
AU (1) | AU2019384462A1 (ja) |
SG (1) | SG11202105242TA (ja) |
WO (1) | WO2020106075A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022084285A1 (de) * | 2020-10-20 | 2022-04-28 | Strauch Georg | Beschichtetes haar und dessen verwendung |
KR102351485B1 (ko) | 2021-05-24 | 2022-01-17 | (주)올바름디앤비 | 모발 성장 촉진 및 탈모 예방용 화장료 조성물 |
CA3236811A1 (en) * | 2021-11-02 | 2023-05-11 | Lindsay WRAY | Cosmetic and personal care compositions comprising recombinant silk |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4819943B1 (ja) * | 1969-07-11 | 1973-06-18 | ||
JPH02311410A (ja) * | 1989-05-26 | 1990-12-27 | Fuji Sangyo Kk | 育毛剤およびその製造法 |
JP2002212092A (ja) * | 2000-12-26 | 2002-07-31 | Stc Nara Co Ltd | 毛髪成長促進剤組成物 |
WO2006112619A1 (en) * | 2005-03-24 | 2006-10-26 | Medigenes Co., Ltd. | Compositions for treating alopecia or promoting hair growth |
JP2008222671A (ja) * | 2007-03-15 | 2008-09-25 | Seiren Co Ltd | 血管内皮細胞増殖因子産生促進剤および育毛養毛用皮膚外用剤 |
KR101236526B1 (ko) * | 2012-04-03 | 2013-03-20 | 월드웨이(주) | 실크단백질 가수분해물을 포함하는 모발성장 촉진용 조성물 |
JP2013528568A (ja) * | 2010-03-11 | 2013-07-11 | コリア アドバンスド インスティチュート オブ サイエンス アンド テクノロジィ | 高分子量の組み換えシルク蛋白質、またはシルク様蛋白質、及びこれを利用して製造されたマイクロ、またはナノサイズのクモの巣線維、またはクモの巣様繊維 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4596812A (en) | 1976-05-24 | 1986-06-24 | The Upjohn Company | Methods and solutions for treating male pattern alopecia |
US4139619A (en) | 1976-05-24 | 1979-02-13 | The Upjohn Company | 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth |
WO2010146415A1 (en) * | 2009-06-15 | 2010-12-23 | Chemyunion Química Ltda. | Sericin cationic nanoparticles for application in products for hair and dyed hair |
WO2013159101A1 (en) * | 2012-04-20 | 2013-10-24 | Trustees Of Tufts College | Silk fibroin-based personal care compositions |
KR101400971B1 (ko) * | 2012-08-29 | 2014-05-29 | 월드웨이(주) | 실크 단백질의 가수 분해물을 함유하는 모발 성장 촉진용 화장료 조성물 |
WO2015048344A2 (en) * | 2013-09-27 | 2015-04-02 | Tufts University | Silk/platelet composition and use thereof |
KR101765255B1 (ko) * | 2014-12-09 | 2017-08-04 | 한국과학기술원 | rnpA 유전자 발현감소를 통한 재조합단백질의 제조방법 |
US9173921B1 (en) * | 2015-03-23 | 2015-11-03 | Jaehyun Lim | Method of promoting hair growth by administration of bFGF |
WO2017042048A1 (en) * | 2015-09-09 | 2017-03-16 | Unilever N.V. | Use of silk proteins for hair care |
KR101880057B1 (ko) * | 2016-05-10 | 2018-07-19 | (주)화니핀코리아 | 초정탄산수를 함유한 탈모 방지용 헤어케어 화장료 조성물 |
CN113194965A (zh) * | 2018-11-23 | 2021-07-30 | 麦迪克斯生物科技股份有限公司 | 用于治疗伤口的药物组合物 |
-
2018
- 2018-11-23 KR KR1020180146288A patent/KR102363366B1/ko active IP Right Grant
-
2019
- 2019-11-21 EP EP19886811.9A patent/EP3884951A4/en active Pending
- 2019-11-21 US US17/296,310 patent/US20220040261A1/en active Pending
- 2019-11-21 WO PCT/KR2019/016012 patent/WO2020106075A1/ko unknown
- 2019-11-21 AU AU2019384462A patent/AU2019384462A1/en not_active Abandoned
- 2019-11-21 SG SG11202105242TA patent/SG11202105242TA/en unknown
- 2019-11-21 JP JP2021529142A patent/JP7315675B2/ja active Active
- 2019-11-21 CN CN201980086221.6A patent/CN113226339A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4819943B1 (ja) * | 1969-07-11 | 1973-06-18 | ||
JPH02311410A (ja) * | 1989-05-26 | 1990-12-27 | Fuji Sangyo Kk | 育毛剤およびその製造法 |
JP2002212092A (ja) * | 2000-12-26 | 2002-07-31 | Stc Nara Co Ltd | 毛髪成長促進剤組成物 |
WO2006112619A1 (en) * | 2005-03-24 | 2006-10-26 | Medigenes Co., Ltd. | Compositions for treating alopecia or promoting hair growth |
JP2008222671A (ja) * | 2007-03-15 | 2008-09-25 | Seiren Co Ltd | 血管内皮細胞増殖因子産生促進剤および育毛養毛用皮膚外用剤 |
JP2013528568A (ja) * | 2010-03-11 | 2013-07-11 | コリア アドバンスド インスティチュート オブ サイエンス アンド テクノロジィ | 高分子量の組み換えシルク蛋白質、またはシルク様蛋白質、及びこれを利用して製造されたマイクロ、またはナノサイズのクモの巣線維、またはクモの巣様繊維 |
KR101236526B1 (ko) * | 2012-04-03 | 2013-03-20 | 월드웨이(주) | 실크단백질 가수분해물을 포함하는 모발성장 촉진용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
KR102363366B1 (ko) | 2022-02-16 |
SG11202105242TA (en) | 2021-06-29 |
US20220040261A1 (en) | 2022-02-10 |
CN113226339A (zh) | 2021-08-06 |
JP7315675B2 (ja) | 2023-07-26 |
AU2019384462A1 (en) | 2021-07-08 |
WO2020106075A1 (ko) | 2020-05-28 |
KR20200060998A (ko) | 2020-06-02 |
EP3884951A4 (en) | 2022-11-09 |
EP3884951A1 (en) | 2021-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7315675B2 (ja) | 脱毛治療又は毛髪成長促進用の組成物 | |
EP0824316A1 (en) | Compositions and methods for stimulating hair growth | |
KR100617644B1 (ko) | 탈모증 치료 또는 모발 성장 촉진용 조성물 | |
US20200306174A1 (en) | Use of gingival fibroblasts in the treatment of alopecia | |
JP2014506586A (ja) | 化学療法及び放射線療法によって惹起される脱毛症(cria)を予防し、criaの衝撃を低減し、及びcria後の毛髪の再成長の出現を改善するための組成物の新規な使用 | |
JP2022527728A (ja) | 成長因子を含有する脱毛治療又は毛髪成長促進用組成物 | |
US20230144955A1 (en) | Peptide for preventing or treating hair loss, and use thereof | |
JP7135106B2 (ja) | 頭皮頭髪用組成物 | |
TWI476010B (zh) | 促進毛髮生長之組合物 | |
JPS61140513A (ja) | 新規な頭皮向け美髪用組成物 | |
CN114366687B (zh) | 齐酞酸在促进毛发生长中的应用 | |
US7754244B2 (en) | Compositions and methods for treating or preventing hair loss and processes for making the same | |
RU2144366C1 (ru) | Средство, стимулирующее рост волос, и способ его получения | |
CN112206226A (zh) | 樱花素的防脱发和生发用途 | |
JPS63301807A (ja) | 養毛皮膚化粧料 | |
KR20090022671A (ko) | 지방전구세포를 포함하는 발모용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210716 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210716 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220531 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220628 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220922 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230110 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230404 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230620 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230713 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7315675 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |